Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	ATM	ATM Common Stock	ATM Additional Paid-in Capital	Public offering	Public offering Common Stock	Public offering Additional Paid-in Capital	License agreement with Zentalis Pharmaceuticals, Inc	License agreement with Zentalis Pharmaceuticals, Inc Common Stock	License agreement with Zentalis Pharmaceuticals, Inc Additional Paid-in Capital	BMS License Agreement	BMS License Agreement Common Stock	BMS License Agreement Additional Paid-in Capital	Ayala Asset Purchase Agreement	Ayala Asset Purchase Agreement Common Stock	Ayala Asset Purchase Agreement Additional Paid-in Capital	Zentalis Asset Purchase Agreement	Zentalis Asset Purchase Agreement Common Stock	Zentalis Asset Purchase Agreement Additional Paid-in Capital
Balance at Dec. 31, 2023	$ 119,882	$ 4	$ 342,663	$ 22	$ (222,807)
Balance (in shares) at Dec. 31, 2023		43,251,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	15,748		15,748
Issuance of common stock						$ 19,576		$ 19,576	$ 215,410	$ 2	$ 215,408	$ 23,388		$ 23,388	$ 2,699		$ 2,699	$ 50,645		$ 50,645	$ 20,990		$ 20,990
Issuance of common stock (in shares)							2,030,431			11,500,000			2,298,586			230,415			2,175,489			1,805,502
Exercise of stock options	2,024		2,024
Exercise of stock options (in shares)		795,571
Exercise of common stock warrants	3,731		3,731
Exercise of common stock warrants (in shares)		373,057
Unrealized gain (loss) on marketable securities	35			35
Net loss	(292,963)				(292,963)
Balance at Dec. 31, 2024	181,165	$ 6	696,872	57	(515,770)
Balance (in shares) at Dec. 31, 2024		64,460,829
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	25,690		25,690
Issuance of common stock						$ 44,924		$ 44,924	$ 594,102	$ 5	$ 594,097
Issuance of common stock (in shares)						4,625,156	4,625,156			43,676,814
Exercise of stock options	$ 913		913
Exercise of stock options (in shares)	389,493	370,400
Unrealized gain (loss) on marketable securities	$ (57)			$ (57)
Net loss	(212,394)				(212,394)
Balance at Dec. 31, 2025	$ 634,343	$ 11	$ 1,362,496		$ (728,164)
Balance (in shares) at Dec. 31, 2025		113,133,199